Tara Lynn Kieffer Enanta Pharmaceuticals Inc (ENTA) insider trading activity

Tara Lynn Kieffer is Chief Product Strategy Officer of ENANTA PHARMACEUTICALS INC. Currently has a direct ownership of 30,620 shares of ENTA, which is worth approximately $369,277. The most recent transaction as insider was on Dec 05, 2025, when has been sold 2,106 shares (Common Stock) at a price of $14.23 per share, resulting in proceeds of $29,968. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 30.6K

8.54% 3M change

4.49% 12M change

Total Value Held $369,277

Tara Lynn Kieffer Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 05 2025	SELL Open market or private sale	$29,968 $14.23 p/Share	2,106 Reduced 6.44%	30,620 Common Stock
Dec 01 2025	SELL Payment of exercise price or tax liability	$10,632 $14.12 p/Share	753 Reduced 2.25%	32,726 Common Stock
Feb 12 2025	SELL Payment of exercise price or tax liability	$18,592 $5.59 p/Share	3,326 Reduced 9.04%	33,479 Common Stock
Feb 12 2025	BUY Grant, award, or other acquisition	-	7,500 Added 16.93%	36,805 Common Stock
Dec 06 2024	SELL Open market or private sale	$18,400 $8.06 p/Share	2,283 Reduced 7.23%	29,305 Common Stock
Dec 01 2024	SELL Payment of exercise price or tax liability	$6,475 $8.6 p/Share	753 Reduced 2.33%	31,588 Common Stock
Jun 17 2024	SELL Open market or private sale	$89,589 $12.33 p/Share	7,266 Reduced 18.35%	32,341 Common Stock

Feb 12 2024	SELL Payment of exercise price or tax liability	$12,074 $12.41 p/Share	973 Reduced 2.4%	39,607 Common Stock
Feb 12 2024	BUY Grant, award, or other acquisition	-	3,320 Added 7.56%	40,580 Common Stock
Dec 05 2023	SELL Open market or private sale	$20,463 $9.63 p/Share	2,125 Reduced 5.4%	37,260 Common Stock
Dec 01 2023	SELL Payment of exercise price or tax liability	$7,145 $9.49 p/Share	753 Reduced 1.88%	39,385 Common Stock
Feb 13 2023	SELL Payment of exercise price or tax liability	$354,878 $52.77 p/Share	6,725 Reduced 14.35%	40,138 Common Stock
Feb 13 2023	BUY Grant, award, or other acquisition	-	20,997 Added 30.94%	46,863 Common Stock
Dec 01 2022	SELL Payment of exercise price or tax liability	$22,076 $44.33 p/Share	498 Reduced 1.89%	25,866 Common Stock
Nov 23 2022	BUY Grant, award, or other acquisition	-	18,500 Added 41.24%	26,364 Common Stock
Feb 14 2022	SELL Payment of exercise price or tax liability	$34,494 $62.49 p/Share	552 Reduced 6.56%	7,864 Common Stock
Feb 14 2022	BUY Grant, award, or other acquisition	-	1,616 Added 16.11%	8,416 Common Stock
Nov 19 2021	BUY Grant, award, or other acquisition	-	6,800 Added 50.0%	6,800 Common Stock

TLK

Tara Lynn Kieffer

Chief Product Strategy Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ENTA shares.

Notify only if

Value

Insider Trading

Get notified when an Enanta Pharmaceuticals Inc insider buys or sells ENTA shares.

Notify only if

Operation

Value

Type

News

Receive news related to ENANTA PHARMACEUTICALS INC

Track Activities on ENTA

Account